



Evaluation of Role of Androgen Receptor Expression in Invasive Duct Carcinoma of Breast

Thesis

Submitted In Partial Fulfillment of Master Degree in Pathology

BY

Nancy Hussien Mohamed Amin

M.B.B.Ch, Cairo University

Supervisors

Prof. Dr. Badawia Bayoumi Ibrahim

Professor of pathology

Faculty of Medicine - Cairo University

Assistant Prof. Dr. Samar Abdel Monem El Sheikh

Assistant Professor of pathology

Faculty of Medicine - Cairo University

Assistant Prof. Dr. Asmaa Ibrahim Abd El-Aziz Salama

Assistant Professor of pathology

National Cancer Institute - Cairo University

Cairo University

2016

Acknowledgement

*First and foremost, I thank **Allah** (SWT) for answering my prayers and endowing me with patience and knowledge to complete this work.*

*This thesis would not have been possible without the help, support, encouragement and keen supervision with useful suggestions, guidance and patience of my principal supervisors, **Prof. Dr. Badawia Bayoumi**, professor of pathology, Faculty of Medicine, Cairo University, Assistant Prof. Dr. Samar El-Sheikh, assistant professor of pathology, Faculty of Medicine, Cairo University and Assistant Prof. Dr. Asmaa Salama, assistant professor of oncologic pathology, NCI, Cairo University.*

*Many thanks to **Prof. Dr. Manar Moneer**, Professor of statistic and cancer epidemiology, NCI, Cairo University for her help, effort and support to accomplish the statistical work of this study.*

*I would like to thank all my senior colleagues, who as wonderful sisters were always willing to help and give their best suggestions, especially **Dr. Habiba El-Fendy** for providing her experience and valuable researches concerned in breast cancer.*

*I wish to express my gratitude to the whole staff members of pathology departments at the **National Cancer Institute, Cairo University** for their hearted support, encouragement and advices.*

Special thanks for my parents and my husband for their prayers and all the support they have provided me over the years. Their care was the greatest gift anyone has ever given me.

For any errors or inadequacies that may remain in this work, of course, the responsibility is entirely my own.

Abstract

Background: Although breast carcinoma had many targeted biomarkers for its treatment, it is a heterogeneous disease with different outcomes and needs new markers especially for the triple negative group when estrogen, progesterone receptors and Her2/neu are negative. Androgen receptor is a new target with unclear role. **The aim of this study** was to examine the prevalence of androgen receptors in invasive duct carcinoma and to elucidate its relation to breast carcinoma subtypes and established clinicopathological factors. **Material and Methods:** One hundred and eleven cases of invasive duct carcinoma were evaluated for age, grade, tumor size, stage and node status. Also, they were analysed immunohistochemically for estrogen receptor, progesterone receptor, Her2/neu and androgen receptor expression. Androgen receptor expression was correlated with histopathological factors, breast cancer subtypes and 2-years DFS. **Results:** Androgen receptor was expressed in 72.1% of cases. It was significantly associated with hormone receptor(s) expression. It was also expressed in a significant number of triple negative breast carcinoma (44%). AR positive breast cancer cases have better prognosis than those with AR negative breast cancer (80% versus 67.7%). **Conclusion:** Although the impact of androgen receptor on breast cancer outcomes had not been clearly established, this result may provide evidence that androgen receptor is a good prognostic and predictive marker. AR could be a new target for the treatment of TNBC group.

LIST OF CONTENTS

Introduction	1
Aim of work	3
Review of Literature	4
• Breast anatomy and histology	4
• Breast carcinoma	6
➤ Epidemiology	6
➤ Risk factors	7
• WHO classification of epithelial tumors of breast	15
• Invasive carcinoma of no special type, NST	20
➤ Histologic picture and grading	21
• Tumor stage	23
➤ AJCC cancer staging changes from sixth to seventh edition	23
• Prognostic and predictive factors.....	27
• Molecular subtypes of breast carcinoma	31
• Steroid hormone receptor proteins	36
➤ Relationship between ER/PR and breast carcinoma	37
➤ Significance of ER and PR receptor status	37

➤ Definition of positive and negative ER and PR tests	39
➤ ASCO recommendations for ER and PR test	40
• Androgen receptor	41
➤ Role of androgen receptor in breast cancer.....	43
➤ AR directed therapies.....	45
• HER2/neu	46
➤ Assessment of HER2/neu status	46
➤ Anti-HER2 Herceptin in Breast Cancer	48
• Ki-67.....	48
➤ The clinical value of ki-67 immunostaining	49
Materials and Methods	51
Results	58
Discussion	84
Summary	93
Conclusions and recommendations	95
References	96
Arabic Summary	119

LIST OF Diagrams

	<i>Page</i>
Diagram (1): Diagrammatic representation of mammary gland (Rosai et al., 2011)	4
Diagram (2) Action of tamoxifen on ER positive breast cancer (Kleinsmith et al, 2010)	39
Diagram (3): Diagrammatic description of Allred Score (Choudhury et al., 2010)	40
Diagram (4): Genomic organization of the AR gene (Germann, 2002)	42
Diagram (5): A ribbon diagram of the AR LBD is shown with ligand in the binding pocket (Germann, 2002)	43
Diagram (6): Schematic of signaling crosstalk between androgen receptor and epidermal growth factor (Garay and Park, 2012)	45
Diagram (7): Algorithm for evaluation of human epidermal growth factor 2 (HER2) protein expression by immunohistochemistry (IHC) assay of the invasive component of a breast cancer specimen (Wolff et al., 2013)	47
Diagram (8): Frequency distribution of studied cases according to laterality	58
Diagram (9): Frequency distribution of studied cases according to location	58
Diagram (10): Frequency distribution of studied cases according to tumor size	59
Diagram (11): Frequency distribution of tumor grades among the studied cases	60
Diagram (12): Frequency distribution of lymph node status among studied cases	61
Diagram (13): Frequency distribution of different metastatic sites	62
Diagram (14): Frequency distribution of studied cases according to surgical procedure	63
Diagram (15): Distribution of breast cancer subtypes among studied cases	65
Diagram (16): Distribution of AR among studied cases	65
Diagram (17): Association between AR and patient's age	66

Diagram (18): Association between AR and tumor grades	67
Diagram (19): Association between AR and nodal status	68
Diagram (20): Association between AR and (T) stage	68
Diagram (21): Association between AR and (N) stage	69
Diagram (22): Association between AR and anatomic stage	70
Diagram (23): Association between AR and hormone receptors	70
Diagram (24): Association between AR and HER2/neu	71
Diagram (25): Association between AR and breast cancer subtypes	72
Diagram (26): DFS in relation to age of the studied cases	75
Diagram (27): DFS in relation to tumor size of the studied cases	75
Diagram (28): DFS in relation to hormone receptor status of the studied cases	76
Diagram (29): DFS in relation to HER2/neu status of the studied cases	76
Diagram (30): DFS in relation to AR status of the studied cases	76
Diagram (31): DFS in relation to anatomic stage of the studied cases	77
Diagram (32): DFS in relation to breast cancer subtypes	77
Diagram (33): Schematic of signaling crosstalk between androgen receptor and epidermal growth factor receptor pathways. Concurrent signaling via androgen receptor with the epidermal growth factor receptor (left) leads to cell cycle arrest. Signaling via one or the other pathway (right) leads to growth proliferation. p21 is required for AR signaling in either situation (Garay and Park, 2012)	89

LIST OF Figures

	<i>Page</i>
Figure (1): Normal histology of the breast (Hassiotou and Geddes, 2013).....	5
Figure (2): Invasive duct carcinoma. Tumor with stellate border and chalky white streaks of necrosis (Rosai et al., 2011).....	20
Figure (3): Prototypical invasive ductal carcinoma (Rosai et al., 2011).....	21
Figure (4): A case of invasive duct carcinoma, grade II, showing ductal formation in 10% of tumor and moderate pleomorphism and mitosis 8/10HPF, insit illustrated mitotic figures, (hematoxylin and eosin; Olympus BX51, original magnification X400)	78
Figure (5): A case of invasive duct carcinoma, grade III with no ductal differentiation, marked pleomorphism and high mitotic activity >20/10HPF, insit illustrated mitotic figures (hematoxylin and eosin; Olympus BX51, original magnification X400)	78
Figure (6): A case of invasive duct carcinoma, grade II associated with Paget’s disease, (hematoxylin and eosin; Olympus BX51, original magnification X200)	79
Figure (7): Lymph node metastasis in a case of invasive duct carcinoma, grade II, showing nodal capsule invasion by tumor cells, (hematoxylin and eosin; Olympus BX51, original magnification X200)	79
Figure (8): A case of invasive duct carcinoma, grade II, in a female patient 62 years old, stage T2N1M0, classified as luminal HER2-negative. (A) Hematoxylin and eosin; original magnification X200. (B) ER: (positive), (C) PR: (positive), (D) HER2/neu: negative, score (0) and (E) AR: (positive); 48% (AR was expressed in 82.9% of luminal HER2-negative subtype), original magnification x200 in (B-E)	80
Figure (9): A case of invasive duct carcinoma, grade II, in a female patient 72 years old, stage T2N1M0, classified as luminal HER2/neu. (A) Hematoxylin and eosin; original magnification X200. (B) ER: (positive), (C) PR: (positive), (D) HER2/neu: positive, score (3) and (E) AR: (positive); 82% (AR was expressed in 68.8% of HER2/neu-positive subtype), original magnification x200 in (B-E)	81
Figure (10): A case of invasive duct carcinoma, grade II, in a female patient 60 years old, stage T2N3M0, classified as HER2/neu enriched. (A) Hematoxylin and eosin; original magnification X200. (B) ER: (negative), (C) PR: (negative), (D) HER2/neu:	

positive, score (3), (E) AR (positive); 70% (AR was expressed in 68.8% of HER2/neu-positive subtype), original magnification X200 in (B-E) **82**

Figure (11): A case of invasive duct carcinoma, grade III, in a female patient 35 years old, stage T2N3M0, classified as TNBC. (A) Hematoxylin and eosin; original magnification x200. (B) ER: (negative), (C) PR: (negative), (D) HER2/neu: negative, score (0). (E) AR: (Positive); 80% (AR was expressed in 44% of TNBC subtype), original magnification x200 in (B-E) **83**

LIST OF TABLES

	<i>Page</i>
Table (1): Nottingham combined histologic grade (Ellis et al., 2012)	22
Table (2): TNM staging system of breast cancer, 7 th edition (Edge and Compton., 2010)	25
Table (3): Immunohistochemical Criteria for Defining Breast Cancer Molecular Subtypes (Voduc et al., 2010)	35
Table (4): Systemic treatment recommendations for subtypes (Goldhirsch et al., 2011)	35
Table (5): Nottingham combined histologic grade (Ellis at al., 2012)	52
Table (6): HER2/neu score used to evaluate Hercept Test (Wolff et al., 2013)	53
Table (7): The used primary antibody	54
Table (8): TNM staging system of breast cancer, 7 th edition (Edge and Compton., 2010)	55
Table (9): Distribution of tumor size among studied cases	59
Table (10): Frequency distribution of tumor grades among the studied cases	60
Table (11): Frequency distribution according to extent of DCIS among studied cases...	60
Table (12): Frequency distribution of lymph nodal status among studied cases	61
Table (13): Distribution of tumor anatomic stage among studied cases	62
Table (14): Distribution of hormonal therapy among the cases	63
Table (15): Distribution of hormone receptors among the cases	64
Table (16): Distribution of HER2/neu among the cases	64
Table (17): Distribution of breast cancer subtypes among studied cases	64

Table (18): Distribution of AR among studied cases	65
Table (19): Association between AR and patient's age	66
Table (20): Association between AR and tumor grades	67
Table (21): Association between AR and nodal status	67
Table (22): Association between AR and (T) stage	68
Table (23): Association between AR and (N) stage	69
Table (24): Association between AR and anatomic stage	69
Table (25): Association between AR and hormone receptors	70
Table (26): Association between AR and HER2/neu	71
Table (27): Association between AR and breast cancer subtypes	72
Table (28): Disease free survival (DFS) in relation to prognostic factors	74

LIST OF ABBREVIATIONS

- **ADH:** Atypical ductal hyperplasia
- **AgNOR:** Argyrophilic nucleolar organizer regions
- **AJCC:** American Joint Committee on Cancer
- **ALH:** Atypical lobular hyperplasia
- **AR:** Androgen receptor
- **ASCO:** American Society of Clinical Oncology
- **ATM:** Ataxia telangiectasia mutated
- **BC:** breast cancer
- **BCS:** breast conservative surgery
- **BM:** bone marrow.
- **BMI:** body mass index
- **BrdU:** Thymidine labeling index, bromodeoxyuridine
- **CDK:** cyclin-dependent kinase
- **CISH:** Chromogenic in situ hybridization
- **DAB:** 3, 3' diaminobenzinetetrachloride
- **DCIS:** Ductal carcinoma in situ
- **DHEA:** Dehydroepiandrosterone
- **DIN:** Ductal intraepithelial neoplasia

- **DFS:** Disease free survival
- **EGFR:** epidermal growth factor receptor
- **ELISA:** enzyme-linked immunosorbent assay
- **ER:** Estrogen receptor
- **ERK:** Extracellular-signal regulated kinase
- **ETD:** extralobular terminal duct
- **FISH:** Fluorescence in situ hybridization
- **HER2:** The human epidermal growth factor receptor 2 gene
- **HER/ErbB:** human epidermal growth factor
- **HT:** Hormonal therapy
- **H & E:** hematoxinilin and eosin staining
- **IARC:** International Agency for Research and Cancer
- **IDC:** invasive ductal carcinoma
- **IHC:** immunohistochemistry
- **IM:** internal mammary node
- **ITD:** intralobular terminal duct
- **(i+):** +ve by IHC
- **Ki-67 LI:** Ki-67 labeling index
- **LBD:** ligand binding domain
- **LCIS:** Lobular carcinoma in situ

- **LIN:** Lobular intraepithelial neoplasia
- **LFS:** Li-Fraumeni syndrome
- **LN:** lymph node
- **LR:** local recurrence
- **M:** distant metastases
- **MAP kinase:** mitogen activated protein kinase
- **MoAbs:** Monoclonal antibodies
- **MRI:** Magnetic resonance imaging
- **N:** regional lymph nodes
- **NBF:** Neutral buffered formalin
- **NCCN:** National Comprehensive Cancer Network
- **NCI:** National Cancer Institute
- **NGS:** Nottingham Grading System
- **NOS:** not otherwise specified
- **NST:** no special type
- **PAI-1:** plasminogen activator inhibitor-1
- **PARP inhibitors:** Poly(ADP-Ribose)polymerase inhibitors
- **PCB's:** polychlorinated biphenyls
- **PCR:** polymerase chain reaction
- **pCR:** pathologic complete response